Health & Wellness

Living with type 1 diabetes while the research moves: questions and answers

By Victor Nwosu · · 7 min read

Living with type 1 diabetes while the research moves: questions and answers

November is National Diabetes Month in the United States, and November 14 is World Diabetes Day, chosen because it is the birthday of Frederick Banting, who with Charles Best and colleagues in Toronto isolated insulin in the early 1920s. Insulin turned type 1 diabetes from a fatal illness into a manageable one. A century later, wearable sensors and smarter pumps have changed the daily work of managing it, and the research pipeline has started to produce treatments aimed at the disease itself.

This piece answers the questions people with type 1 diabetes and their families most often ask about that research, in general terms. It is not medical advice. Decisions about devices, drugs or trials belong in a conversation with your own diabetes care team.

What is type 1 diabetes, briefly?

It is an autoimmune disease. The immune system attacks the beta cells in the pancreas, which sit in small clusters called islets and make insulin. Without enough insulin, glucose builds up in the blood while the body's cells go short of fuel. People with type 1 diabetes need insulin from outside, every day, delivered by injection or pump. It is different from type 2 diabetes, which is far more common and starts mainly with the body responding poorly to insulin.

Researchers now describe type 1 in stages. In stage 1, a person has two or more of the autoantibodies linked to the disease but normal blood sugar. In stage 2, blood sugar has started to run abnormal, still without symptoms. Stage 3 is the point most people know as diagnosis, when symptoms such as thirst, weight loss and fatigue appear.

How is a continuous glucose monitor different from finger-stick testing?

A finger-stick meter gives one reading at one moment. A continuous glucose monitor, or CGM, uses a small sensor worn on the skin, usually on the arm or abdomen, with a thin filament just under the surface. It measures glucose in the fluid between cells every few minutes and sends readings to a phone or receiver.

The difference is the trend. A reading of 120 mg/dL means one thing if it is steady and another if it is falling fast. CGMs show direction, can sound alarms before a low, and record patterns overnight that a meter would never catch. They do have limits: sensors lag behind blood glucose by several minutes, need replacing on a schedule, can be knocked off, and sometimes still need a finger-stick to confirm a reading that does not match how a person feels.

What does "time in range" mean?

It is the share of the day a person's glucose stays within a target band, most often 70 to 180 mg/dL. An international consensus published in 2019 in the journal Diabetes Care suggested that many adults with type 1 diabetes aim for more than 70 percent of readings in that band, with targets adjusted for children, older adults and pregnancy. Time in range sits alongside the long-standing HbA1c blood test rather than replacing it. Your care team sets the targets that apply to you.

What is automated insulin delivery?

Sometimes called a hybrid closed loop or, informally, an artificial pancreas, it links a CGM to an insulin pump through software. The algorithm raises or lowers background insulin every few minutes based on the sensor's readings and where glucose is heading. The FDA approved the first such hybrid system in September 2016, and several more have followed, including some that work with tubeless patch pumps and some cleared for young children.

"Hybrid" is the important word. Most systems still need the user to announce meals and take a mealtime dose, because insulin given after eating acts too slowly to catch a rise caused by carbohydrates. The systems also depend on a working sensor, a working pump site and a charged phone or controller. They take a lot of work off a person's plate. They do not take all of it.

Is there a treatment that delays the disease?

Yes, for some people. In November 2022 the FDA approved teplizumab (sold as Tzield) to delay the onset of stage 3 type 1 diabetes in people aged 8 and older who are already in stage 2. It is an antibody given as an intravenous infusion once a day for 14 days. In the trial behind the approval, people who received it reached stage 3 later, on average, than those who received a placebo, though many still went on to develop it. In April 2026 the FDA extended the approval to children as young as 1 year old in stage 2.

Teplizumab does not cure the disease or reverse stage 3. Its use depends on knowing someone is in stage 2, which in turn depends on antibody screening. Relatives of people with type 1 diabetes have a higher chance of carrying the autoantibodies, and screening programs, including the NIH-funded TrialNet network, have offered testing to family members for years. Common side effects listed for the drug include a temporary drop in some white blood cells, rash and headache.

Where do islet transplants and stem cell treatments fit?

This is the area with the most headlines and the most confusion, so it helps to separate three things.

First, transplants of donor islets. In June 2023 the FDA approved Lantidra, made from islet cells taken from deceased donors' pancreases and infused into the liver. It is approved for a narrow group of adults with type 1 diabetes who cannot reach their glucose targets because of repeated severe low blood sugar episodes despite intensive management. Recipients need lifelong drugs to suppress the immune system, which carry their own risks, and donor supply is limited.

Second, islet cells grown from stem cells. Several groups have learned to turn pluripotent stem cells into cells that make insulin. One such product has moved into a phase 3 stage, and early results published in the New England Journal of Medicine in 2025 reported that most participants given the cells were able to stop or sharply reduce insulin injections. Those participants also took immune-suppressing drugs. Our reference page on stem cells and type 1 diabetes explains how these cells are made and what the trials are designed to show.

Third, approaches meant to avoid immune suppression altogether, by wrapping cells in protective devices or editing them so the immune system overlooks them. These are earlier, mostly in small first-in-human studies, and results so far are mixed.

None of these is a routine option for most people with type 1 diabetes. Clinics advertising stem cell injections that "reverse diabetes" for a cash fee are not offering any of the three. The FDA and the International Society for Stem Cell Research both warn against unapproved stem cell treatments, and our checklist of warning signs at unproven stem cell clinics covers how to spot them.

How would I find a legitimate trial?

Real trials are registered. The US registry at ClinicalTrials.gov lists studies of devices, drugs and cell therapies for type 1 diabetes, with eligibility criteria, locations and contacts. Our guide to reading a ClinicalTrials.gov listing explains how to tell a phase 1 safety study from a later trial and how to read the eligibility section. Many cell replacement trials enroll only adults with long-standing disease and severe hypoglycemia, because the risks of immune suppression are easier to justify for that group.

Legitimate trials rarely charge participants for the experimental treatment, and a request for a large fee is a warning sign. Your endocrinologist can help judge whether a given study is a reasonable fit.

Where can I read more from public health agencies?

The National Institute of Diabetes and Digestive and Kidney Diseases, part of the NIH, publishes plain-language material on type 1 diabetes at niddk.nih.gov. The CDC's diabetes pages cover day-to-day management, including advice on preparing for sick days and emergencies.

What should I take from all this in daily life?

Day to day, the tools that make the biggest difference are the ones already approved: sensors, pumps, automated systems and a care team that knows how to use them. Research timelines are long, and the most promising cell therapies are being tested first in people with the hardest-to-control disease. A practical question to bring to the next clinic appointment is a narrow one: given my age, my numbers and my insurance, which of the approved devices or screening options am I not using yet, and why?

This explainer is general information, not medical advice. Decisions about treatment, donation or trials belong with a clinician who knows your history.

More on this topic